, Tracking Stock Market Picks
Enter Symbol:
Cyclacel Pharmaceuticals, Inc. (CYCC) [hlAlert]

down 98.60 %

Cyclacel Pharmaceuticals, Inc. (CYCC) rated Buy with price target $9 by Cantor Fitzgerald

Posted on: Wednesday,  Mar 12, 2008  2:25 PM ET by Cantor Fitzgerald

Cantor Fitzgerald rated Buy Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) on 03/12/2008. Previously Cantor Fitzgerald rated Buy Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) on
11/27/2007., when the stock price was $37.31. Since then, Cyclacel Pharmaceuticals, Inc. has lost 98.61% as of 08/27/2015's recent price of $0.52.
If you would have followed the previous Cantor Fitzgerald's recommendation on CYCC, you would have lost 98.6% of your investment in 2830 days.

Cyclacel Pharmaceuticals, Inc. (Cyclacel) is a development-stage biopharmaceutical company engaged in the discovery, development and commercialization of mechanism-targeted drugs to treat human cancers and other serious disorders. The Company markets, directly in the United States, Xclair Cream for radiation dermatitis, and Numoisyn Liquid and Numoisyn Lozenges for xerostomia through its wholly owned subsidiary, ALIGN Pharmaceuticals, LLC (ALIGN). Cyclacel focuses primarily on the development of orally available anticancer agents that target the cell cycle with the aim of slowing the progression or shrinking the size of tumors. The Company has been focusing on the cell cycle since its inception. On January 13, 2009, it announced that the Company began treating patients in a Phase II, open label, single arm, multicenter clinical trial of sapacitabine in patients with non-small cell lung cancer (NSCLC) who have had one prior chemotherapy.

Cantor U.S. Equity Research provides timely and insightful opinions on select stocks. We look at key drivers of the stock price, including company and industry fundamentals, capital markets influences and overall economic trends to provide critical and in-depth analysis. Our focus is on small and mid-cap companies in the following sectors: * Marine Transportation * Life Sciences * Clean Technology & Energy Efficiency * Real Estate * Communications Technology * Internet * Enterprise Software
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/12/2008 2:25 PM Buy
20.72 63.00
as of 12/24/2008
1 Week up  24.00 %
1 Month up  47.61 %
3 Months up  72.22 %
1 YTD up  47.61 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/27/2007 9:25 AM Buy
37.31 73.50

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy